Active client · Clinical-stage biotech
US$4.6MSeries A closed about 90 days in
12+media mentions
500+patients asked to join its study
Long-form interviews with both founders and coverage in biotech outlets. The story also reached Business Insider, Yahoo Finance, Morningstar and MarketWatch through distribution and syndication. After the campaign, the company reported inbound investor interest.
“What stood out most was their ability to understand the science behind our clinical program and translate complex information into clear, compelling messaging for the right audiences.”

Franco VigileCo-Founder and CEO, N-Zyme Biomedical